Resource Logo

Antiretroviral therapy with stavudine (d4T) in patients (pts) who have failed or are intolerant to AZT and ddI.


Natl Conf Hum Retroviruses Relat Infect (1st). 1993 Dec 12-16;:130.

Efficacy and safety of d4T was studied in 36 pts who failed or were intolerant to AZT and DDI, weighed greater than 60 kg. 2 doses, 15 (dose A) and 30 mg (dose B) b.i.d. were given. All pts were ambulatory, with less than 300 CD4+, 5 pts had elevated P24 antigen at baseline and over half had experienced AIDS-related Kaposi's sarcoma or opportunistic infections. 7 pts were excluded from analysis due to protocol violation or being on study less than 1 month. 23 pts were randomized to dose A and 6 to dose B. Mean duration of therapy is 110 days. 13 of 23 with dose A showed a rise in CD4+ cells over baseline after a mean of 60 days which persists at 90 days. 10 pts had a fall in CD4+ cells from baseline and 3 were unchanged. P24 antigen remained unchanged. With dose B all 6 pts showed a rise in CD4+ cells at 1 month of starting d4T but no change in P24 antigen. 3 pts in this group died of AIDS. 4 pts were taken off study due to drug associated neuropathy (2), pancreatitis (1) & diabetes mellitus (1). We conclude from these studies that d4T is an effective and safe antiretroviral agent.

Acyclovir/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Comparative Study Drug Therapy, Combination Human HIV Core Protein p24/*BLOOD Longitudinal Studies Zidovudine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE ABSTRACT


Information in this article was accurate in December 30, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.